Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1CNS 1

Conditions

Prostatic Neoplasms 1Glioma 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Administration, Oral × Clear all
NCT06559007 2025-03-18

Phase 1 Study to Evaluate PK, Safety, and Tolerability of HRS-5041 in Healthy Caucasian Male Participants

Atridia Pty Ltd.

Phase 1 Completed
24 enrolled
Genitourinary

Prostatic Neoplasms

NCT01167322 2012-04-27

Study of NPC-07 for Fluorescence-guided Resection of Malignant Gliomas

Nobelpharma

Phase 3 Completed
45 enrolled
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡